214 related articles for article (PubMed ID: 15297138)
1. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
[TBL] [Abstract][Full Text] [Related]
2. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
Ataman F; Poortmans P; Davis JB; Bernier J; Giraud JY; Kouloulias VE; Pierart M; Bolla M
Eur J Cancer; 2004 Nov; 40(16):2411-6. PubMed ID: 15519513
[TBL] [Abstract][Full Text] [Related]
3. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Sydes MR; Graham JD; Aird EG; Bottomley D; Cowan RA; Huddart RA; Jose CC; Matthews JH; Millar J; Moore AR; Morgan RC; Russell JM; Scrase CD; Stephens RJ; Syndikus I; Parmar MK;
Lancet Oncol; 2007 Jun; 8(6):475-87. PubMed ID: 17482880
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.
Mason MD; Moore R; Jones G; Lewis G; Donovan JL; Neal DE; Hamdy FC; Lane JA; Staffurth JN;
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e92-e100. PubMed ID: 27425582
[TBL] [Abstract][Full Text] [Related]
5. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Jovic G; Syndikus I; Khoo V; Cowan RA; Graham JD; Aird EG; Bottomley D; Huddart RA; Jose CC; Matthews JH; Millar JL; Murphy C; Russell JM; Scrase CD; Parmar MK; Sydes MR
Lancet Oncol; 2014 Apr; 15(4):464-73. PubMed ID: 24581940
[TBL] [Abstract][Full Text] [Related]
6. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial.
Seddon B; Bidmead M; Wilson J; Khoo V; Dearnaley D
Radiother Oncol; 2000 Jul; 56(1):73-83. PubMed ID: 10869758
[TBL] [Abstract][Full Text] [Related]
7. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397).
Mayles WP; Moore AR; Aird EG; Bidmead AM; Dearnaley DP; Griffiths SE; Warrington AP;
Radiother Oncol; 2004 Nov; 73(2):199-207. PubMed ID: 15622611
[TBL] [Abstract][Full Text] [Related]
8. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).
Dearnaley DP; Sydes MR; Langley RE; Graham JD; Huddart RA; Syndikus I; Matthews JH; Scrase CD; Jose CC; Logue J; Stephens RJ;
Radiother Oncol; 2007 Apr; 83(1):31-41. PubMed ID: 17391791
[TBL] [Abstract][Full Text] [Related]
9. A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer.
Moore AR; Warrington AP; Aird EG; Bidmead AM; Dearnaley DP
Radiother Oncol; 2006 Jul; 80(1):82-5. PubMed ID: 16828908
[TBL] [Abstract][Full Text] [Related]
10. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).
Syndikus I; Morgan RC; Sydes MR; Graham JD; Dearnaley DP;
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):773-83. PubMed ID: 19836155
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).
Mangar SA; Sydes MR; Tucker HL; Coffey J; Sohaib SA; Gianolini S; Webb S; Khoo VS; ; Dearnaley DP
Radiother Oncol; 2006 Sep; 80(3):355-62. PubMed ID: 16949694
[TBL] [Abstract][Full Text] [Related]
12. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
[TBL] [Abstract][Full Text] [Related]
13. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
[TBL] [Abstract][Full Text] [Related]
14. Development of a dosimetry inter-comparison for IMRT as part of site credentialing for a TROG multi-centre clinical trial for prostate cancer.
Healy B; Frantzis J; Murry R; Martin J; Middleton M; Catton C; Kron T
Australas Phys Eng Sci Med; 2011 Jun; 34(2):195-202. PubMed ID: 21424814
[TBL] [Abstract][Full Text] [Related]
15. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.
Haworth A; Kearvell R; Greer PB; Hooton B; Denham JW; Lamb D; Duchesne G; Murray J; Joseph D
Radiother Oncol; 2009 Mar; 90(3):299-306. PubMed ID: 19017549
[TBL] [Abstract][Full Text] [Related]
16. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
Dearnaley DP; Khoo VS; Norman AR; Meyer L; Nahum A; Tait D; Yarnold J; Horwich A
Lancet; 1999 Jan; 353(9149):267-72. PubMed ID: 9929018
[TBL] [Abstract][Full Text] [Related]
17. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
18. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Ataman F; Poortmans P; Stupp R; Fisher B; Mirimanoff RO
Eur J Cancer; 2004 Jul; 40(11):1724-30. PubMed ID: 15251162
[TBL] [Abstract][Full Text] [Related]
19. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.
Creak A; Hall E; Horwich A; Eeles R; Khoo V; Huddart R; Parker C; Griffin C; Bidmead M; Warrington J; Dearnaley D
Br J Cancer; 2013 Aug; 109(3):651-7. PubMed ID: 23880826
[TBL] [Abstract][Full Text] [Related]
20. Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).
Stanley S; Griffiths S; Sydes MR; Moore AR; Syndikus I; Dearnaley DP;
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):582-90. PubMed ID: 18565744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
